Xu, Wenxin

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

Nassar, A. H., Adib, E., Abou Alaiwi, S., El Zarif, T., Groha, S., Akl, E. W., Nuzzo, P. V., Mouhieddine, T. H., Perea-Chamblee, T., Taraszka, K., et al. (2022) · Cancer Cell

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 121

Natural Language Processing to Ascertain Cancer Outcomes from Medical Oncologist Notes

Kehl, K. L., Xu, W., Lepisto, E., Elmarakeby, H., Hassett, M. J., Van Allen, E. M., Johnson, B. E., & Schrag, D. (2020) · JCO Clinical Cancer Informatics

Machine Learning in HealthcareBiomedical Text Mining and Ontologies

Cited by 90

Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial.

Saliby, R. M., Machaalani, M., Zhong, C., Alves Costa Silva, C., Labaki, C., Saad, E., Steiner, C., Yekeduz, E., Eid, M., Daoud Khatoun, W., et al. (2025) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 2